Psychoneuroimmunology

Last updated

Psychoneuroimmunology (PNI), also referred to as psychoendoneuroimmunology (PENI) or psychoneuroendocrinoimmunology (PNEI), is the study of the interaction between psychological processes and the nervous and immune systems of the human body. [1] [2] It is a subfield of psychosomatic medicine. PNI takes an interdisciplinary approach, incorporating psychology, neuroscience, immunology, physiology, genetics, pharmacology, molecular biology, psychiatry, behavioral medicine, infectious diseases, endocrinology, and rheumatology.

Contents

The main interests of PNI are the interactions between the nervous and immune systems and the relationships between mental processes and health. [3] PNI studies, among other things, the physiological functioning of the neuroimmune system in health and disease; disorders of the neuroimmune system (autoimmune diseases; hypersensitivities; immune deficiency); and the physical, chemical and physiological characteristics of the components of the neuroimmune system in vitro, in situ, and in vivo.

History

Interest in the relationship between psychiatric syndromes or symptoms and immune function has been a consistent theme since the beginning of modern medicine.

Claude Bernard, the father of modern physiology, with his pupils Claude Bernard and his pupils. Oil painting after Leon-Augus Wellcome V0017769.jpg
Claude Bernard, the father of modern physiology, with his pupils

Claude Bernard, a French physiologist of the Muséum national d'Histoire naturelle (National Museum of Natural History in English), formulated the concept of the milieu interieur in the mid-1800s. In 1865, Bernard described the perturbation of this internal state: "... there are protective functions of organic elements holding living materials in reserve and maintaining without interruption humidity, heat and other conditions indispensable to vital activity. Sickness and death are only a dislocation or perturbation of that mechanism" (Bernard, 1865). Walter Cannon, a professor of physiology at Harvard University coined the commonly used term, homeostasis, in his book The Wisdom of the Body, 1932, from the Greek word homoios, meaning similar, and stasis, meaning position. In his work with animals, Cannon observed that any change of emotional state in the beast, such as anxiety, distress, or rage, was accompanied by total cessation of movements of the stomach (Bodily Changes in Pain, Hunger, Fear and Rage, 1915). These studies looked into the relationship between the effects of emotions and perceptions on the autonomic nervous system, namely the sympathetic and parasympathetic responses that initiated the recognition of the freeze, fight or flight response. His findings were published from time to time in professional journals, then summed up in book form in The Mechanical Factors of Digestion, published in 1911.

Bust of Hans Selye at Selye Janos University, Komarno, Slovakia Hans Selye.JPG
Bust of Hans Selye at Selye János University, Komárno, Slovakia

Hans Selye, a student of Johns Hopkins University and McGill University, and a researcher at Université de Montréal, experimented with animals by putting them under different physical and mental adverse conditions and noted that under these difficult conditions the body consistently adapted to heal and recover. Several years of experimentation that formed the empiric foundation of Selye's concept of the General Adaptation Syndrome. This syndrome consists of an enlargement of the adrenal gland, atrophy of the thymus, spleen, and other lymphoid tissue, and gastric ulcerations.

Selye describes three stages of adaptation, including an initial brief alarm reaction, followed by a prolonged period of resistance, and a terminal stage of exhaustion and death. This foundational work led to a rich line of research on the biological functioning of glucocorticoids. [4]

Mid-20th century studies of psychiatric patients reported immune alterations in psychotic individuals, including lower numbers of lymphocytes [5] [6] and poorer antibody response to pertussis vaccination, compared with nonpsychiatric control subjects. [7] In 1964, George F. Solomon, from the University of California in Los Angeles, and his research team coined the term "psychoimmunology" and published a landmark paper: "Emotions, immunity, and disease: a speculative theoretical integration." [8]

Origins

In 1975, Robert Ader and Nicholas Cohen, at the University of Rochester, advanced PNI with their demonstration of classic conditioning of immune function, and they subsequently coined the term "psychoneuroimmunology". [9] [10] Ader was investigating how long conditioned responses (in the sense of Pavlov's conditioning of dogs to drool when they heard a bell ring) might last in laboratory rats. To condition the rats, he used a combination[ clarification needed ] of saccharin-laced water (the conditioned stimulus) and the drug Cytoxan, which unconditionally induces nausea and taste aversion and suppression of immune function. Ader was surprised to discover that after conditioning, just feeding the rats saccharin-laced water was associated with the death of some animals and he proposed that they had been immunosuppressed after receiving the conditioned stimulus. Ader (a psychologist) and Cohen (an immunologist) directly tested this hypothesis by deliberately immunizing conditioned and unconditioned animals, exposing these and other control groups to the conditioned taste stimulus, and then measuring the amount of antibody produced. The highly reproducible results revealed that conditioned rats exposed to the conditioned stimulus were indeed immunosuppressed. In other words, a signal via the nervous system (taste) was affecting immune function. This was one of the first scientific experiments that demonstrated that the nervous system can affect the immune system.

In the 1970s, Hugo Besedovsky, Adriana del Rey and Ernst Sorkin, working in Switzerland, reported multi-directional immune-neuro-endocrine interactions, since they show that not only the brain can influence immune processes but also the immune response itself can affect the brain and neuroendocrine mechanisms. They found that the immune responses to innocuous antigens triggers an increase in the activity of hypothalamic neurons [11] [12] and hormonal and autonomic nerve responses that are relevant for immunoregulation and are integrated at brain levels (see review [13] ). On these bases, they proposed that the immune system acts as a sensorial receptor organ that, besides its peripheral effects, can communicate to the brain and associated neuro-endocrine structures its state of activity. [12] These investigators also identified products from immune cells, later characterized as cytokines, that mediate this immune-brain communication [14] (more references in [13] ).

In 1981, David L. Felten, then working at the Indiana University School of Medicine, and his colleague JM Williams, discovered a network of nerves leading to blood vessels as well as cells of the immune system. The researchers also found nerves in the thymus and spleen terminating near clusters of lymphocytes, macrophages, and mast cells, all of which help control immune function. This discovery provided one of the first indications of how neuro-immune interaction occurs.

Ader, Cohen, and Felten went on to edit the groundbreaking book Psychoneuroimmunology in 1981, which laid out the underlying premise that the brain and immune system represent a single, integrated system of defense.

In 1985, research by neuropharmacologist Candace Pert, of the National Institutes of Health at Georgetown University, revealed that neuropeptide-specific receptors are present on the cell walls of both the brain and the immune system. [15] [16] The discovery that neuropeptides and neurotransmitters act directly upon the immune system shows their close association with emotions and suggests mechanisms through which emotions, from the limbic system, and immunology are deeply interdependent. Showing that the immune and endocrine systems are modulated not only by the brain but also by the central nervous system itself affected the understanding of emotions, as well as disease.

Contemporary advances in psychiatry, immunology, neurology, and other integrated disciplines of medicine has fostered enormous growth for PNI. The mechanisms underlying behaviorally induced alterations of immune function, and immune alterations inducing behavioral changes, are likely to have clinical and therapeutic implications that will not be fully appreciated until more is known about the extent of these interrelationships in normal and pathophysiological states.

The immune-brain loop

PNI research looks for the exact mechanisms by which specific neuroimmune effects are achieved. Evidence for nervous-immunological interactions exist at multiple biological levels.

The immune system and the brain communicate through signaling pathways. The brain and the immune system are the two major adaptive systems of the body. Two major pathways are involved in this cross-talk: the Hypothalamic-pituitary-adrenal axis (HPA axis), and the sympathetic nervous system (SNS), via the sympathetic-adrenal-medullary axis (SAM axis). The activation of SNS during an immune response might be aimed to localize the inflammatory response.

The body's primary stress management system is the HPA axis. The HPA axis responds to physical and mental challenge to maintain homeostasis in part by controlling the body's cortisol level. Dysregulation of the HPA axis is implicated in numerous stress-related diseases, with evidence from meta-analyses indicating that different types/duration of stressors and unique personal variables can shape the HPA response. [17] HPA axis activity and cytokines are intrinsically intertwined: inflammatory cytokines stimulate adrenocorticotropic hormone (ACTH) and cortisol secretion, while, in turn, glucocorticoids suppress the synthesis of proinflammatory cytokines.

Molecules called pro-inflammatory cytokines, which include interleukin-1 (IL-1), Interleukin-2 (IL-2), interleukin-6 (IL-6), Interleukin-12 (IL-12), Interferon-gamma (IFN-Gamma) and tumor necrosis factor alpha (TNF-alpha) can affect brain growth as well as neuronal function. Circulating immune cells such as macrophages, as well as glial cells (microglia and astrocytes) secrete these molecules. Cytokine regulation of hypothalamic function is an active area of research for the treatment of anxiety-related disorders. [18]

Cytokines mediate and control immune and inflammatory responses. Complex interactions exist between cytokines, inflammation and the adaptive responses in maintaining homeostasis. Like the stress response, the inflammatory reaction is crucial for survival. Systemic inflammatory reaction results in stimulation of four major programs: [19]

These are mediated by the HPA axis and the SNS. Common human diseases such as allergy, autoimmunity, chronic infections and sepsis are characterized by a dysregulation of the pro-inflammatory versus anti-inflammatory and T helper (Th1) versus (Th2) cytokine balance.[ medical citation needed ] Recent studies show pro-inflammatory cytokine processes take place during depression, mania and bipolar disease, in addition to autoimmune hypersensitivity and chronic infections. [20]

Chronic secretion of stress hormones, glucocorticoids (GCs) and catecholamines (CAs), as a result of disease, may reduce the effect of neurotransmitters, including serotonin, norepinephrine and dopamine, or other receptors in the brain, thereby leading to the dysregulation of neurohormones. [20] Under stimulation, norepinephrine is released from the sympathetic nerve terminals in organs, and the target immune cells express adrenoreceptors. Through stimulation of these receptors, locally released norepinephrine, or circulating catecholamines such as epinephrine, affect lymphocyte traffic, circulation, and proliferation, and modulate cytokine production and the functional activity of different lymphoid cells.

Glucocorticoids also inhibit the further secretion of corticotropin-releasing hormone from the hypothalamus and ACTH from the pituitary (negative feedback). Under certain conditions stress hormones may facilitate inflammation through induction of signaling pathways and through activation of the corticotropin-releasing hormone.

These abnormalities and the failure of the adaptive systems to resolve inflammation affect the well-being of the individual, including behavioral parameters, quality of life and sleep, as well as indices of metabolic and cardiovascular health, developing into a "systemic anti-inflammatory feedback" and/or "hyperactivity" of the local pro-inflammatory factors which may contribute to the pathogenesis of disease.

This systemic or neuro-inflammation and neuroimmune activation have been shown to play a role in the etiology of a variety of neurodegenerative disorders such as Parkinson's and Alzheimer's disease, multiple sclerosis, pain, and AIDS-associated dementia. However, cytokines and chemokines also modulate central nervous system (CNS) function in the absence of overt immunological, physiological, or psychological challenges. [21]

Psychoneuroimmunological effects

There are now sufficient data to conclude that immune modulation by psychosocial stressors and/or interventions can lead to actual health changes. Although changes related to infectious disease and wound healing have provided the strongest evidence to date, the clinical importance of immunological dysregulation is highlighted by increased risks across diverse conditions and diseases. For example, stressors can produce profound health consequences. In one epidemiological study, all-cause mortality increased in the month following a severe stressor – the death of a spouse. [22] Theorists propose that stressful events trigger cognitive and affective responses which, in turn, induce sympathetic nervous system and endocrine changes, and these ultimately impair immune function. [23] [24] Potential health consequences are broad, but include rates of infection [25] [26] HIV progression [27] [28] cancer incidence and progression, [22] [29] [30] and high rates of infant mortality. [31] [32]

Understanding stress and immune function

Stress is thought to affect immune function through emotional and/or behavioral manifestations such as anxiety, fear, tension, anger and sadness and physiological changes such as heart rate, blood pressure, and sweating. Researchers have suggested that these changes are beneficial if they are of limited duration, [23] but when stress is chronic, the system is unable to maintain equilibrium or homeostasis; the body remains in a state of arousal, where digestion is slower to reactivate or does not reactivate properly, often resulting in indigestion. Furthermore, blood pressure stays at higher levels. [33]

In one of the earlier PNI studies, which was published in 1960, subjects were led to believe that they had accidentally caused serious injury to a companion through misuse of explosives. [34] Since then decades of research resulted in two large meta-analyses, which showed consistent immune dysregulation in healthy people who are experiencing stress.

In the first meta-analysis by Herbert and Cohen in 1993, [35] they examined 38 studies of stressful events and immune function in healthy adults. They included studies of acute laboratory stressors (e.g. a speech task), short-term naturalistic stressors (e.g. medical examinations), and long-term naturalistic stressors (e.g. divorce, bereavement, caregiving, unemployment). They found consistent stress-related increases in numbers of total white blood cells, as well as decreases in the numbers of helper T cells, suppressor T cells, and cytotoxic T cells, B cells, and natural killer cells (NK). They also reported stress-related decreases in NK and T cell function, and T cell proliferative responses to phytohaemagglutinin [PHA] and concanavalin A [Con A]. These effects were consistent for short-term and long-term naturalistic stressors, but not laboratory stressors.

In the second meta-analysis by Zorrilla et al. in 2001, [36] they replicated Herbert and Cohen's meta-analysis. Using the same study selection procedures, they analyzed 75 studies of stressors and human immunity. Naturalistic stressors were associated with increases in number of circulating neutrophils, decreases in number and percentages of total T cells and helper T cells, and decreases in percentages of natural killer cell (NK) cells and cytotoxic T cell lymphocytes. They also replicated Herbert and Cohen's finding of stress-related decreases in NKCC and T cell mitogen proliferation to phytohaemagglutinin (PHA) and concanavalin A (Con A).

A study done by the American Psychological Association did an experiment on rats, where they applied electrical shocks to a rat, and saw how interleukin-1 was released directly into the brain. Interleukin-1 is the same cytokine released when a macrophage chews on a bacterium, which then travels up the vagus nerve, creating a state of heightened immune activity, and behavioral changes. [37]

More recently, there has been increasing interest in the links between interpersonal stressors and immune function. For example, marital conflict, loneliness, caring for a person with a chronic medical condition, and other forms on interpersonal stress dysregulate immune function. [38]

Communication between the brain and immune system

Communication between neuroendocrine and immune system

Connections between glucocorticoids and immune system

Corticotropin-releasing hormone (CRH)

Release of corticotropin-releasing hormone (CRH) from the hypothalamus is influenced by stress. [44]

Furthermore, stressors that enhance the release of CRH suppress the function of the immune system; conversely, stressors that depress CRH release potentiate immunity.

Relationships between prefrontal cortex activation and cellular senescence

Pharmaceutical advances

Glutamate agonists, cytokine inhibitors, vanilloid-receptor agonists, catecholamine modulators, ion-channel blockers, anticonvulsants, GABA agonists (including opioids and cannabinoids), COX inhibitors, acetylcholine modulators, melatonin analogs (such as Ramelton), adenosine receptor antagonists and several miscellaneous drugs (including biologics like Passiflora edulis) are being studied for their psychoneuroimmunological effects.

For example, SSRIs, SNRIs and tricyclic antidepressants acting on serotonin, norepinephrine, dopamine and cannabinoid receptors have been shown to be immunomodulatory and anti-inflammatory against pro-inflammatory cytokine processes, specifically on the regulation of IFN-gamma and IL-10, as well as TNF-alpha and IL-6 through a psychoneuroimmunological process. [47] [48] [49] [50] Antidepressants have also been shown to suppress TH1 upregulation. [47] [48] [49] [51] [52]

Tricyclic and dual serotonergic-noradrenergic reuptake inhibition by SNRIs (or SSRI-NRI combinations), have also shown analgesic properties additionally. [53] [54] According to recent evidences antidepressants also seem to exert beneficial effects in experimental autoimmune neuritis in rats by decreasing Interferon-beta (IFN-beta) release or augmenting NK activity in depressed patients. [18]

These studies warrant investigation of antidepressants for use in both psychiatric and non-psychiatric illness and that a psychoneuroimmunological approach may be required for optimal pharmacotherapy in many diseases. [55] Future antidepressants may be made to specifically target the immune system by either blocking the actions of pro-inflammatory cytokines or increasing the production of anti-inflammatory cytokines. [56]

The endocannabinoid system appears to play a significant role in the mechanism of action of clinically effective and potential antidepressants and may serve as a target for drug design and discovery. [50] The endocannabinoid-induced modulation of stress-related behaviors appears to be mediated, at least in part, through the regulation of the serotoninergic system, by which cannabinoid CB1 receptors modulate the excitability of dorsal raphe serotonin neurons. [57] Data suggest that the endocannabinoid system in cortical and subcortical structures is differentially altered in an animal model of depression and that the effects of chronic, unpredictable stress (CUS) on CB1 receptor binding site density are attenuated by antidepressant treatment while those on endocannabinoid content are not.

The increase in amygdalar CB1 receptor binding following imipramine treatment is consistent with prior studies which collectively demonstrate that several treatments which are beneficial to depression, such as electroconvulsive shock and tricyclic antidepressant treatment, increase CB1 receptor activity in subcortical limbic structures, such as the hippocampus, amygdala and hypothalamus. And preclinical studies have demonstrated the CB1 receptor is required for the behavioral effects of noradrenergic based antidepressants but is dispensable for the behavioral effect of serotonergic based antidepressants. [58] [59]

Extrapolating from the observations that positive emotional experiences boost the immune system, Roberts speculates that intensely positive emotional experiences—sometimes brought about during mystical experiences occasioned by psychedelic medicines—may boost the immune system powerfully. Research on salivary IgA supports this hypothesis, but experimental testing has not been done. [60]

See also

Related Research Articles

<span class="mw-page-title-main">Stress (biology)</span> Organisms response to a stressor such as an environmental condition or a stimulus

Stress, whether physiological, biological or psychological, is an organism's response to a stressor such as an environmental condition. Stress is the body's method of reacting to a condition such as a threat, challenge or physical and psychological barrier. There are two hormones that an individual produces during a stressful situation, well known as adrenaline and cortisol. There are two kinds of stress hormone levels. Resting (basal) cortisol levels are normal everyday quantities that are essential for standard functioning. Reactive cortisol levels are increases in cortisol in response to stressors. Stimuli that alter an organism's environment are responded to by multiple systems in the body. In humans and most mammals, the autonomic nervous system and hypothalamic-pituitary-adrenal (HPA) axis are the two major systems that respond to stress.

<span class="mw-page-title-main">Cytokine</span> Broad and loose category of small proteins important in cell signaling

Cytokines are a broad and loose category of small proteins important in cell signaling. Due to their size, cytokines cannot cross the lipid bilayer of cells to enter the cytoplasm and therefore typically exert their functions by interacting with specific cytokine receptors on the target cell surface. Cytokines have been shown to be involved in autocrine, paracrine and endocrine signaling as immunomodulating agents.

<span class="mw-page-title-main">Hypothalamic–pituitary–adrenal axis</span> Set of physiological feedback interactions

The hypothalamic–pituitary–adrenal axis is a complex set of direct influences and feedback interactions among three components: the hypothalamus, the pituitary gland, and the adrenal glands. These organs and their interactions constitute the HPA axis.

Interleukins (ILs) are a group of cytokines that are expressed and secreted by white blood cells (leukocytes) as well as some other body cells. The human genome encodes more than 50 interleukins and related proteins.

<span class="mw-page-title-main">Interleukin 4</span> Mammalian protein found in Mus musculus

The interleukin 4 is a cytokine that induces differentiation of naive helper T cells (Th0 cells) to Th2 cells. Upon activation by IL-4, Th2 cells subsequently produce additional IL-4 in a positive feedback loop. IL-4 is produced primarily by mast cells, Th2 cells, eosinophils and basophils. It is closely related and has functions similar to IL-13.

Neuroimmunology is a field combining neuroscience, the study of the nervous system, and immunology, the study of the immune system. Neuroimmunologists seek to better understand the interactions of these two complex systems during development, homeostasis, and response to injuries. A long-term goal of this rapidly developing research area is to further develop our understanding of the pathology of certain neurological diseases, some of which have no clear etiology. In doing so, neuroimmunology contributes to development of new pharmacological treatments for several neurological conditions. Many types of interactions involve both the nervous and immune systems including the physiological functioning of the two systems in health and disease, malfunction of either and or both systems that leads to disorders, and the physical, chemical, and environmental stressors that affect the two systems on a daily basis.

<span class="mw-page-title-main">Neuroimmune system</span>

The neuroimmune system is a system of structures and processes involving the biochemical and electrophysiological interactions between the nervous system and immune system which protect neurons from pathogens. It serves to protect neurons against disease by maintaining selectively permeable barriers, mediating neuroinflammation and wound healing in damaged neurons, and mobilizing host defenses against pathogens.

<span class="mw-page-title-main">Endocannabinoid system</span> Biological system of neurotransmitters

The endocannabinoid system (ECS) is a biological system composed of endocannabinoids, which are endogenous lipid-based retrograde neurotransmitters that bind to cannabinoid receptors, and cannabinoid receptor proteins that are expressed throughout the vertebrate central nervous system and peripheral nervous system. The endocannabinoid system remains under preliminary research, but may be involved in regulating physiological and cognitive processes, including fertility, pregnancy, pre- and postnatal development, various activity of immune system, appetite, pain-sensation, mood, and memory, and in mediating the pharmacological effects of cannabis. The ECS plays an important role in multiple aspects of neural functions, including the control of movement and motor coordination, learning and memory, emotion and motivation, addictive-like behavior and pain modulation, among others.

<span class="mw-page-title-main">Interleukin 19</span> Protein-coding gene in the species Homo sapiens

Interleukin 19 (IL-19) is an immunosuppressive protein that belongs to the IL-10 cytokine subfamily.

A Corticotropin-releasing hormone antagonist is a specific type of receptor antagonist that blocks the receptor sites for corticotropin-releasing hormone, also known as corticotropin-releasing factor (CRF), which synchronizes the behavioral, endocrine, autonomic, and immune responses to stress by controlling the hypothalamic-pituitary-adrenal axis. CRH antagonists thereby block the consequent secretions of ACTH and cortisol due to stress, among other effects.

<span class="mw-page-title-main">Sickness behavior</span> Aspect of psychology

Sickness behavior is a coordinated set of adaptive behavioral changes that develop in ill individuals during the course of an infection. They usually, but not always, accompany fever and aid survival. Such illness responses include lethargy, depression, anxiety, malaise, loss of appetite, sleepiness, hyperalgesia, reduction in grooming and failure to concentrate. Sickness behavior is a motivational state that reorganizes the organism's priorities to cope with infectious pathogens. It has been suggested as relevant to understanding depression, and some aspects of the suffering that occurs in cancer.

<span class="mw-page-title-main">Interleukin-1 family</span> Group of cytokines playing a key role in the regulation of immune and inflammatory responses

The Interleukin-1 family is a group of 11 cytokines that plays a central role in the regulation of immune and inflammatory responses to infections or sterile insults.

The pharmacology of antidepressants is not entirely clear. The earliest and probably most widely accepted scientific theory of antidepressant action is the monoamine hypothesis, which states that depression is due to an imbalance of the monoamine neurotransmitters. It was originally proposed based on the observation that certain hydrazine anti-tuberculosis agents produce antidepressant effects, which was later linked to their inhibitory effects on monoamine oxidase, the enzyme that catalyses the breakdown of the monoamine neurotransmitters. All currently marketed antidepressants have the monoamine hypothesis as their theoretical basis, with the possible exception of agomelatine which acts on a dual melatonergic-serotonergic pathway. Despite the success of the monoamine hypothesis it has a number of limitations: for one, all monoaminergic antidepressants have a delayed onset of action of at least a week; and secondly, there are a sizeable portion (>40%) of depressed patients that do not adequately respond to monoaminergic antidepressants. Further evidence to the contrary of the monoamine hypothesis are the recent findings that a single intravenous infusion with ketamine, an antagonist of the NMDA receptor — a type of glutamate receptor — produces rapid, robust and sustained antidepressant effects. Monoamine precursor depletion also fails to alter mood. To overcome these flaws with the monoamine hypothesis a number of alternative hypotheses have been proposed, including the glutamate, neurogenic, epigenetic, cortisol hypersecretion and inflammatory hypotheses. Another hypothesis that has been proposed which would explain the delay is the hypothesis that monoamines don't directly influence mood, but influence emotional perception biases.

<span class="mw-page-title-main">Raz Yirmiya</span>

Raz Yirmiya is an Israeli behavioral neuroscientist and director of the Laboratory for Psychoneuroimmunology at the Hebrew University of Jerusalem in Israel. He is best known for providing the first experimental evidence for the role of immune system activation in depression, for discovering that disturbances in brain microglia cells underlie some forms of depression, and for elucidating the involvement of inflammatory cytokines in regulation of cognitive and emotional processes.

<span class="mw-page-title-main">Geniposide</span> Chemical compound

Geniposide, the glycoside form of genipin, is a bioactive iridoid glycoside that is found in a wide variety of medicinal herbs, such as Gardenia jasminoides (fruits) . Geniposide shows several pharmacological effects including neuroprotective, antidiabetic, hepatoprotective, anti-inflammatory, analgesic, antidepressant-like, cardioprotective, antioxidant, immune-regulatory, antithrombotic and antitumoral activity. These pharmacology benefits arise through the modulating action of geniposide on several proteins and genes that are associated with inflammatory and oxidative stress processes.

Immuno-psychiatry, according to Pariante, is a discipline that studies the connection between the brain and the immune system. It differs from psychoneuroimmunology by postulating that behaviors and emotions are governed by peripheral immune mechanisms. Depression, for instance, is seen as malfunctioning of the immune system.

<span class="mw-page-title-main">Type 3 innate lymphoid cells</span>

Type 3 innate lymphoid cells (ILC3) are immune cells from the lymphoid lineage that are part of the innate immune system. These cells participate in innate mechanisms on mucous membranes, contributing to tissue homeostasis, host-commensal mutualism and pathogen clearance. They are part of a heterogeneous group of innate lymphoid cells, which is traditionally divided into three subsets based on their expression of master transcription factors as well as secreted effector cytokines - ILC1, ILC2 and ILC3.

Major depression is often associated or correlated with immune function dysregulation, and the two are thought to share similar physiological pathways and risk factors. Primarily seen through increased inflammation, this relationship is bidirectional with depression often resulting in increased immune response and illness resulting in prolonged sadness and lack of activity. This association is seen both long-term and short-term, with the presence of one often being accompanied by the other and both inflammation and depression often being co-morbid with other conditions.

<span class="mw-page-title-main">Keith W. Kelley</span> American immunophysiologist, researcher and academic

Keith Kelley is an American immunophysiologist, researcher and academic. He is Professor Emeritus of Immunophysiology at the University of Illinois and Editor-In-Chief Emeritus of Brain, Behavior, and Immunity. He is a Past-President and Secretary-Treasurer of the Psychoneuroimmunology Research Society.

<span class="mw-page-title-main">Interleukin 17F</span>

Interleukin 17F (IL-17F) is signaling protein that is in human is encoded by the IL17F gene and is considered a pro-inflammatory cytokine. This protein belongs to the interleukin 17 family and is mainly produced by the T helper 17 cells after their stimulation with interleukin 23. However, IL-17F can be also produced by a wide range of cell types, including innate immune cells and epithelial cells.

References

  1. ↑ Michael Irwin, Kavita Vedhara (2005). Human Psychoneuroimmunology. Oxford University Press. ISBN   978-0-19-856884-1.
  2. ↑ Segerstrom, Suzanne C., ed. (2012). The Oxford handbook of psychoneuroimmunology. New York: Oxford University Press. ISBN   9780195394399. OCLC   775894214.
  3. ↑ Betts, J Gordon; Desaix, Peter; Johnson, Eddie; Johnson, Jody E; Korol, Oksana; Kruse, Dean; Poe, Brandon; Wise, James; Womble, Mark D; Young, Kelly A (June 8, 2023). Anatomy & Physiology. Houston: OpenStax CNX. 21.7 Transplantation and cancer immunology. ISBN   978-1-947172-04-3.
  4. ↑ Neylan Thomas C (1998). "Hans Selye and the Field of Stress Research". J Neuropsychiatry Clin Neurosci. 10 (2): 230. doi:10.1176/jnp.10.2.230.
  5. ↑ Freeman H, Elmadjian F (1947). "The relationship between blood sugar and lymphocyte levels in normal and psychotic subjects". Psychosom Med. 9 (4): 226–33. doi:10.1097/00006842-194707000-00002. PMID   20260255. S2CID   35806157.
  6. ↑ Phillips L, Elmadjian F (1947). "A Rorschach tension score and the diurnal lymphocyte curve in psychotic subjects". Psychosom Med. 9 (6): 364–71. doi:10.1097/00006842-194711000-00002. PMID   18913449. S2CID   2210570.
  7. ↑ Vaughan WT, Sullivan JC, Elmadjian F (1949). "Immunity and schizophrenia". Psychosom Med. 11 (6): 327–33. doi:10.1097/00006842-194911000-00001. PMID   15406182. S2CID   30835205.
  8. ↑ Solomon GF, Moos RH. Emotions, immunity, and disease: a speculative theoretical integration. Arch Gen Psychiatry 1964; 11: 657–74
  9. ↑ R Ader and N Cohen. Behaviorally conditioned immunosuppression. Psychosomatic Medicine, Vol 37, Issue 4 333-340
  10. ↑ "Robert Ader, Founder of Psychoneuroimmunology, Dies". University of Rochester Medical Center . 2011-12-20. Retrieved 2011-12-20.
  11. ↑ Besedovsky, H.; Sorkin, E.; Felix, D.; Haas, H. (May 1977). "Hypothalamic changes during the immune response". European Journal of Immunology. 7 (5): 323–325. doi:10.1002/eji.1830070516. ISSN   0014-2980. PMID   326564. S2CID   224774815.
  12. 1 2 Besedovsky, H.; del Rey, A.; Sorkin, E.; Da Prada, M.; Burri, R.; Honegger, C. (1983-08-05). "The immune response evokes changes in brain noradrenergic neurons". Science. 221 (4610): 564–566. Bibcode:1983Sci...221..564B. doi:10.1126/science.6867729. ISSN   0036-8075. PMID   6867729.
  13. 1 2 Besedovsky, Hugo O.; Rey, Adriana Del (January 2007). "Physiology of psychoneuroimmunology: a personal view". Brain, Behavior, and Immunity. 21 (1): 34–44. doi:10.1016/j.bbi.2006.09.008. ISSN   0889-1591. PMID   17157762. S2CID   24279481.
  14. ↑ Besedovsky, H.; del Rey, A.; Sorkin, E.; Dinarello, C. A. (1986-08-08). "Immunoregulatory feedback between interleukin-1 and glucocorticoid hormones". Science. 233 (4764): 652–654. Bibcode:1986Sci...233..652B. doi:10.1126/science.3014662. ISSN   0036-8075. PMID   3014662.
  15. ↑ Pert CB, Ruff MR, Weber RJ, Herkenham M. "Neuropeptides and their receptors: a psychosomatic network" J Immunol 1985 Aug;135(2 Suppl):820s-826s
  16. ↑ Ruff M, Schiffmann E, Terranova V, Pert CB (Dec 1985). "Neuropeptides are chemoattractants for human tumor cells and monocytes: a possible mechanism for metastasis". Clin Immunol Immunopathol. 37 (3): 387–96. doi:10.1016/0090-1229(85)90108-4. PMID   2414046.
  17. ↑ Miller, Gregory E.; Chen, Edith; Zhou, Eric S. (January 2007). "If it goes up, must it come down? Chronic stress and the hypothalamic-pituitary-adrenocortical axis in humans". Psychological Bulletin. 133 (1): 25–45. doi:10.1037/0033-2909.133.1.25. PMID   17201569.
  18. 1 2 Covelli V, Passeri ME, Leogrande D, Jirillo E, Amati L (2005). "Drug targets in stress-related disorders". Curr. Med. Chem. 12 (15): 1801–9. doi:10.2174/0929867054367202. PMID   16029148.
  19. ↑ Elenkov IJ (2005). "Cytokine dysregulation, inflammation and well-being". Neuroimmunomodulation. 12 (5): 255–69. doi:10.1159/000087104. PMID   16166805. S2CID   39185155.
  20. 1 2 Hall, Rudolph (2011-06-11). Narcissistic behavior in the postmodern era : the study of neuropsychology. p. 136. ISBN   9781462884193.
  21. ↑ "PA-05-054: Functional Links between the Immune System, Brain Function and Behavior". grants.nih.gov.
  22. 1 2 Kaprio J.; Koskenvuo M.; Rita H. (1987). "Mortality after bereavement: a prospective study of 95,647 widowed persons". American Journal of Public Health. 77 (3): 283–7. doi:10.2105/ajph.77.3.283. PMC   1646890 . PMID   3812831.
  23. 1 2 Chrousos, G. P. and Gold, P. W. (1992). The concepts of stress and stress system disorders. Overview of physical and behavioral homeostasis. JAMA 267(Mar 4), 1244-52.
  24. ↑ Glaser, R. and Kiecolt-Glaser, J. K. (1994). Handbook of Human Stress and Immunity. San Diego: Academic Press.
  25. ↑ Cohen S.; Tyrrell D. A.; Smith A. P. (1991). "Psychological stress and susceptibility to the common cold". The New England Journal of Medicine. 325 (9): 606–12. doi: 10.1056/nejm199108293250903 . PMID   1713648.
  26. ↑ Cohen S.; Williamson G. M. (1991). "Stress and infectious disease in humans". Psychological Bulletin. 109 (1): 5–24. doi:10.1037/0033-2909.109.1.5. PMID   2006229.
  27. ↑ Leserman J.; Petitto J. M.; Golden R. N.; Gaynes B. N.; Gu H.; Perkins D. O.; Silva S. G.; Folds J. D.; Evans D. L. (2000). "Impact of stressful life events, depression, social support, coping, and cortisol on progression to AIDS". The American Journal of Psychiatry. 157 (8): 1221–8. doi:10.1176/appi.ajp.157.8.1221. PMID   10910783.
  28. ↑ Leserman J.; Jackson E. D.; Petitto J. M.; Golden R. N.; Silva S. G.; Perkins D. O.; Cai J.; Folds J. D.; Evans D. L. (1999). "Progression to AIDS: the effects of stress, depressive symptoms, and social support". Psychosomatic Medicine. 61 (3): 397–406. doi:10.1097/00006842-199905000-00021. PMID   10367622.
  29. ↑ Andersen B. L.; Kiecolt-Glaser J. K.; Glaser R. (1994). "A biobehavioral model of cancer stress and disease course". American Psychologist. 49 (5): 389–404. doi:10.1037/0003-066x.49.5.389. PMC   2719972 . PMID   8024167.
  30. ↑ Kiecolt-Glaser J. K.; Glaser R. (1999). "Psychoneuroimmunology and cancer: fact or fiction?". European Journal of Cancer. 35 (11): 1603–7. doi:10.1016/s0959-8049(99)00197-5. PMID   10673969.
  31. ↑ Osel, Joseph, D. (2008). "Being (Born) Black in America: Perceived Discrimination & African American Infant Mortality", The Evergreen State College Symposium on Psychoneuroimmunology; SSRN.
  32. ↑ Collins J. W.; David R.; Handler A.; Wall S.; Andes S. (2004). "Very low birthweight in African American infants: The role of maternal exposure to interpersonal racial discrimination". American Journal of Public Health. 94 (12): 2132–2138. doi:10.2105/ajph.94.12.2132. PMC   1448603 . PMID   15569965.
  33. ↑ Gasperin, Daniela; Netuveli, Gopalakrishnan; Dias-da-Costa, Juvenal Soares; Pattussi, Marcos Pascoal (April 2009). "Effect of psychological stress on blood pressure increase: a meta-analysis of cohort studies". Cadernos de Saúde Pública. 25 (4): 715–726. doi: 10.1590/S0102-311X2009000400002 .
  34. ↑ McDonald RD, Yagi K (1960). "A note on eosinopenia as an index of psychological stress". Psychosom Med. 2 (22): 149–50. doi:10.1097/00006842-196003000-00007. S2CID   147391585.
  35. ↑ Herbert TB, Cohen S (1993). "Stress and immunity in humans: a meta-analytic review". Psychosom. Med. 55 (4): 364–379. CiteSeerX   10.1.1.125.6544 . doi:10.1097/00006842-199307000-00004. PMID   8416086. S2CID   2025176.
  36. ↑ Zorrilla E. P.; Luborsky L.; McKay J. R.; Rosenthal R.; Houldin A.; Tax A.; McCorkle R.; Seligman D. A.; Schmidt K. (2001). "The relationship of depression and stressors to immunological assays: a meta-analytic review". Brain, Behavior, and Immunity. 15 (3): 199–226. doi:10.1006/brbi.2000.0597. PMID   11566046. S2CID   21106219.
  37. ↑ Azar, Beth (December 2001). "A new take on psychoneuroimmunology". Monitor on Psychology 32(11). American Psychological Association. Retrieved 2019-03-19.
  38. ↑ Jaremka, L.M. (2013). "Synergistic relationships among stress, depression, and troubled relationships: Insights from Psychoneuroimmunology". Depression and Anxiety. 30 (4): 288–296. doi:10.1002/da.22078. PMC   3816362 . PMID   23412999.
  39. ↑ Sumner R.C.; Parton A.; Nowicky A.N.; Kishore U.; Gidron Y. (2011-12-15). "Hemispheric lateralisation and immune function: A systematic review of human research" (PDF). Journal of Neuroimmunology. 240–241: 1–12. doi:10.1016/j.jneuroim.2011.08.017. PMID   21924504. S2CID   10127202.
  40. ↑ Papanicolaou DA, Wilder RL, Manolagas SC, Chrousos GP (1998). "The pathophysiologic roles of interleukin-6 in human disease". Ann Intern Med. 128 (2): 127–137. doi:10.7326/0003-4819-128-2-199801150-00009. PMID   9441573. S2CID   37260638.
  41. ↑ Carlson, Neil R. (2013). Physiology of behavior (11th ed.). Boston: Pearson. p. 611. ISBN   978-0205239399.
  42. ↑ "Adrenal Fatigue 101 — Leah Hosburgh Leah Hosburgh Nutritonal Therapy". Leah Hosburgh. Retrieved 2020-12-07.
  43. 1 2 3 Janicki-Deverts, Denise; Cohen, Sheldon; Turner, Ronald B.; Doyle, William J. (March 2016). "Basal salivary cortisol secretion and susceptibility to upper respiratory infection". Brain, Behavior, and Immunity. 53: 255–261. doi:10.1016/j.bbi.2016.01.013. PMC   4783177 . PMID   26778776.
  44. 1 2 3 Luecken, Linda; Gall, Linda; Nicolson, Nancy (2007). "Chapter 3: Measurement of Cortisol". Handbook of Physiological Research Methods in Health Psychology. SAGE Publications. pp. 37–44. ISBN   9781412926058.
  45. ↑ Thayer JF, Ahs F, Fredrikson M, et al. (December 2012). "A meta-analysis of heart rate variability and neuroimaging studies: implications for heart rate variability as a marker of stress and health". Neurosci Biobehav Rev. 36 (2): 747–756. doi:10.1016/j.neubiorev.2011.11.009. PMID   22178086. S2CID   2512272.
  46. ↑ Williams DP, Koenig J, Carnevali L, et al. (August 2019). "Heart rate variability and inflammation: A meta-analysis of human studies". Brain Behav. Immun. 80: 219–226. doi:10.1016/j.bbi.2019.03.009. PMID   30872091. S2CID   78091147.
  47. 1 2 Kubera M, Lin AH, Kenis G, Bosmans E, van Bockstaele D, Maes M (Apr 2001). "Anti-Inflammatory effects of antidepressants through suppression of the interferon-gamma/interleukin-10 production ratio". J Clin Psychopharmacol. 21 (2): 199–206. doi:10.1097/00004714-200104000-00012. PMID   11270917. S2CID   43429490.
  48. 1 2 Maes M."The immunoregulatory effects of antidepressants". Hum Psychopharmacol. 2001 Jan;16(1) 95-103
  49. 1 2 Maes M, Kenis G, Kubera M, De Baets M, Steinbusch H, Bosmans E."The negative immunoregulatory effects of fluoxetine in relation to the cAMP-dependent PKA pathway". Int Immunopharmacol. 2005 Mar;5(3) 609-18.
  50. 1 2 Smaga, Irena; Bystrowska, Beata; Gawliński, Dawid; Pomierny, Bartosz; Stankowicz, Piotr; Filip, Małgorzata (2014). "Antidepressants and Changes in Concentration of Endocannabinoids and N-Acylethanolamines in Rat Brain Structures". Neurotoxicity Research. 26 (2): 190–206. doi:10.1007/s12640-014-9465-0. ISSN   1029-8428. PMC   4067538 . PMID   24652522.
  51. ↑ Diamond M, Kelly JP, Connor TJ (Oct 2006). "Antidepressants suppress production of the Th1 cytokine interferon-gamma, independent of monoamine transporter blockade". Eur Neuropsychopharmacol. 16 (7): 481–90. doi:10.1016/j.euroneuro.2005.11.011. PMID   16388933. S2CID   12983560.
  52. ↑ Brustolim D, Ribeiro-dos-Santos R, Kast RE, Altschuler EL, Soares MB (Jun 2006). "A new chapter opens in anti-inflammatory treatments: the antidepressant bupropion lowers production of tumor necrosis factor-alpha and interferon-gamma in mice" (PDF). Int Immunopharmacol. 6 (6): 903–7. doi:10.1016/j.intimp.2005.12.007. PMID   16644475.
  53. ↑ Moulin DE, Clark AJ, Gilron I, Ware MA, Watson CP, Sessle BJ, Coderre T, Morley-Forster PK, Stinson J, Boulanger A, Peng P, Finley GA, Taenzer P, Squire P, Dion D, Cholkan A, Gilani A, Gordon A, Henry J, Jovey R, Lynch M, Mailis-Gagnon A, Panju A, Rollman GB, Velly A (Spring 2007). "Pharmacological management of chronic neuropathic pain - consensus statement and guidelines from the Canadian Pain Society". Pain Res Manag. 12 (1): 13–21. doi: 10.1155/2007/730785 . PMC   2670721 . PMID   17372630.
  54. ↑ Jones CK, Eastwood BJ, Need AB, Shannon HE (Dec 2006). "Analgesic effects of serotonergic, noradrenergic or dual reuptake inhibitors in the carrageenan test in rats: evidence for synergism between serotonergic and noradrenergic reuptake inhibition". Neuropharmacology. 51 (7–8): 1172–80. doi:10.1016/j.neuropharm.2006.08.005. PMID   17045620. S2CID   23871569.
  55. ↑ Kulmatycki KM, Jamali F (2006). "Drug disease interactions: role of inflammatory mediators in depression and variability in antidepressant drug response". J Pharm Pharm Sci. 9 (3): 292–306. PMID   17207413.
  56. ↑ O'Brien SM, Scott LV, Dinan TG (Aug 2004). "Cytokines: abnormalities in major depression and implications for pharmacological treatment". Hum Psychopharmacol. 19 (6): 397–403. doi:10.1002/hup.609. PMID   15303243. S2CID   11723122.
  57. ↑ Haj-Dahmane, Samir; Shen, Roh-Yu (September 2011). "Modulation of the Serotonin System by Endocannabinoid Signaling". Neuropharmacology. 61 (3): 414–420. doi:10.1016/j.neuropharm.2011.02.016. ISSN   0028-3908. PMC   3110547 . PMID   21354188.
  58. ↑ Hill, Matthew N.; Carrier, Erica J.; McLaughlin, Ryan J.; Morrish, Anna C.; Meier, Sarah E.; Hillard, Cecilia J.; Gorzalka, Boris B. (September 2008). "Regional Alterations in the Endocannabinoid System in an Animal Model of Depression: Effects of Concurrent Antidepressant Treatment". Journal of Neurochemistry. 106 (6): 2322–2336. doi:10.1111/j.1471-4159.2008.05567.x. ISSN   0022-3042. PMC   2606621 . PMID   18643796.
  59. ↑ Hill, Matthew N.; Barr, Alasdair M.; Ho, W.-S. Vanessa; Carrier, Erica J.; Gorzalka, Boris B.; Hillard, Cecilia J. (2007-10-01). "Electroconvulsive shock treatment differentially modulates cortical and subcortical endocannabinoid activity". Journal of Neurochemistry. 103 (1): 47–56. doi: 10.1111/j.1471-4159.2007.04688.x . ISSN   1471-4159. PMID   17561935.
  60. ↑ Roberts, Thomas B. (2006). "Chapter 6. Do Entheogen-induced Mystical Experiences Boost the Immune System?: Psychedelics, Peak Experiences, and Wellness". Psychedelic Horizons. Westport, CT: Praeger/Greenwood.

Further reading

This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.